Trialant
Platform
Home
Studies
Other
Contact Us
Terms of Service
Privacy Policy
Toggle Sidebar
Studies
Study
JSON
Overview
Key facts that identify this study and show where it stands today.
Description
What the study is about and why it is being run, in the researchers' own words.
Conditions
The medical conditions and diseases this study investigates.
Interventions
The treatments and procedures being evaluated in this study.
Participation
Who can join this study and the criteria used to decide.
Design
How the study is designed and how its participant groups are organized.
Contacts
The people to reach with questions about this study or how to join it.
Locations
Where the study is run and whether each site is currently recruiting.
Collaborators
The organizations and people involved in this study.
Similar Studies
Other registered studies that closely resemble this one.
Workspace
Home
Studies
Collections
Views
Contact Us
Terms of Service
Privacy Policy
Sign up
NCT00454753
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
NCT00339144
Completed
Interventional
Phase 1
Updated Dec 15, 2010
A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate
NCT00298987
Completed
Interventional
Phase 2
Updated Feb 8, 2010
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
NCT00371345
Completed
Interventional
Phase 2
Updated Apr 26, 2011
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
NCT00316953
Completed
Interventional
Phase 1
Updated Feb 5, 2013
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
NCT00459108
Terminated
Interventional
Phase 2
Updated Apr 19, 2018
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
NCT00349518
Withdrawn
Interventional
Phase 2
Phase 3
Updated Feb 17, 2016
Expanded Access for Dasatinib | NCT00454753 | Trialant
Save
Share
No longer available
Expanded Access
Updated Apr 29, 2022
Expanded Access for Dasatinib
ClinicalTrials.gov ID
NCT00454753
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY
Overall Status
No longer available
Study Type
Expanded Access
Last Update Posted
Apr 29, 2022
Actual
Brief Summary
This is an expanded access designed to provide access to dasatinib for eligible participants.
No conditions
There are no conditions for this study.
Dasatinib
Ages Eligible for Study
Child (0-17)
Adult (18-64)
Older Adult (65+)
Sexes Eligible for Study
No data available
Accepts Healthy Volunteers
No data available
Eligibility Criteria
No data available
No design
There is no design for this study.
No central contacts
There are no central contacts for this study.
No locations
There are no locations for this study.
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY